2022 Outlook
In 2022, Valneva expects to continue investing strongly in its R&D programs and increase vaccine sales, subject to regulatory approval of VLA2001.
Our Financials & Outlook
2022 Financial Guidance
- Total revenues between €430 to €590 million expected, including:
- €350 to €500 million of COVID-19 vaccine sales, subject to regulatory approvals and deliveries of VLA2001[1],
- €60 to €70 million of other vaccine sales
- Approximately €20 million of Other Revenues (revenues from collaborations, licensing and services)
- R&D expenses expected between €160 million and €200 million
1 Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001